Skip to content
Wellness Wisdom: Your Path to Optimal Health — Understand & Nurture Your Mind — Mastering Business Growth — technology

PharmAla Biotech Launches NEXUS: A New Tool for MDMA-Assisted Therapy

NEXUS simplifies MDMA-assisted therapy. It connects professionals and advances patient access to this innovative treatment.

,   and  Administrator
1 min read
A woman is lying on a stretcher like thing. There is another woman doing a therapy. There are some...
A woman is lying on a stretcher like thing. There is another woman doing a therapy. There are some posters describing the therapy. There are some items and books on a table beside them.

PharmAla Biotech Launches NEXUS: A New Tool for MDMA-Assisted Therapy

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) has launched NEXUS, a new tool to connect Prescribers, Therapists, and Clinic Managers in MDMA-assisted living therapy. The tool aims to simplify regulatory pathways for patient access, share knowledge on advances, and improve patient care.

NEXUS is PharmAla's latest initiative, reflecting the company's 'regulatory first' approach. It is designed to foster better communication and collaboration among medical professionals involved in MDMA-assisted living therapy. The tool is part of PharmAla's commitment to improving patient access to its MDXX class molecules, including MDMA.

PharmAla has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. The company focuses on research, development, and manufacturing of these molecules, making it the only company provisioning clinical-grade MDMA for patient treatments outside of clinical trials.

PharmAla has launched NEXUS to enhance patient care and access to MDMA-assisted living therapy. The company continues to prioritize regulatory excellence and innovative solutions. Interested medical practitioners can learn more about NEXUS at a webinar on October 22, 2022, at 4:00 PM EST.

Read also:

Related

Latest